Stockscreener 앱 받기
0.9522
1.84%
-0.0178
시간 외 거래:
.95
-0.0022
-0.23%
전일 마감가:
$0.97
열려 있는:
$0.98
하루 거래량:
101.27K
Relative Volume:
0.41
시가총액:
$98.86M
수익:
-
순이익/손실:
$-19.50M
주가수익비율:
-6.2645
EPS:
-0.152
순현금흐름:
$-19.09M
1주 성능:
+6.93%
1개월 성능:
+9.45%
6개월 성능:
+17.56%
1년 성능:
+68.53%
1일 변동 폭
$0.9361
$1.00
1주일 범위
$0.875
$1.07
52주 변동 폭
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TLSA | 0.9522 | 98.86M | 0 | -19.50M | -19.09M | -0.152 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2018-12-17 | 개시 | Laidlaw | Buy |
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
Tiziana Life Sciences Secures ALS Trial Funding - Yahoo Finance
Tiziana Life Sciences secures grant for ALS trial - Proactive Investors USA
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - The Manila Times
Tiziana Life Sciences Secures ALS Association Grant for Breakthrough Foralumab Trial | TLSA Stock News - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short Interest - MarketBeat
Tiziana Life Sciences CEO discusses foralumab potential to enhance OzempicICYMI - Proactive Investors USA
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - The Manila Times
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference - Proactive Investors UK
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer’s therapy - Proactive Investors USA
Tiziana Life Sciences Plans Share Sale with Jefferies - MSN
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study - GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - The Manila Times
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - GlobeNewswire Inc.
Tiziana reports progress in obesity inflammation study By Investing.com - Investing.com South Africa
Tiziana Life Sciences : announces plans for clinical development of foralumab, the company’s fully human CD3 antibody - Marketscreener.com
Tiziana Life Sciences' Semaglutide combo shows potential in obesity-related liver inflammation - Proactive Investors USA
TLSATiziana Life Sciences Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity - Proactive Investors UK
Tiziana reports progress in obesity inflammation study - Investing.com
Proactive news headlines: Helix, Hemogenyx, DEC, Ananda, Thor Energy, Bradda Head and more - Proactive Investors UK
Discover October 2024's Promising US Penny Stocks - Simply Wall St
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Tiziana Life Sciences Advances with Promising Drug Trials - Yahoo Finance
Tiziana Life Sciences reports interim results, updates on programs - Investing.com India
Tiziana Life Sciences reports interim results, updates on programs By Investing.com - Investing.com Canada
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update - MarketBeat
High Affinity Nerve Growth Factor Receptor Market constantly growing to See Bigger Picture - IndiaPolitics.com
Thymic Carcinoma Treatment Market Size, Market Resilience and Forecasted Scenarios (2024-2034) - Third Eye News
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Declines By 67.0% - MarketBeat
Base Resources Limited (OTCMKTS:BSRUF) Sees Significant Increase in Short Interest - Defense World
Tiziana Life Sciences Secures $4M Grant for Alzheimer’s Disease Study - European Pharmaceutical Manufacturer
EverSource Wealth Advisors LLC Acquires 330,000 Shares of Signing Day Sports, Inc. (NYSEAMERICAN:SGN) - Defense World
New Pacific Mtl to Post Q1 2025 Earnings of $0.00 Per Share, Raymond James Forecasts (TSE:NUA) - Defense World
iShares ESG Aware MSCI USA ETF (NASDAQ:ESGU) Stock Holdings Lifted by Affinity Capital Advisors LLC - Defense World
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Affinity Capital Advisors LLC Has $4.62 Million Position in Vanguard Short-Term Bond ETF (NYSEARCA:BSV) - Defense World
ENN Energy Holdings Limited (OTCMKTS:XNGSY) Short Interest Up 550.0% in September - Defense World
Thrivent Financial for Lutherans Cuts Holdings in Regal Rexnord Co. (NYSE:RRX) - Defense World
AlTi Global Inc. Sells 1,052 Shares of CVS Health Co. (NYSE:CVS) - Defense World
Tiziana Life Sciences Ltd: Analyzing TLSA Stock Trends - The InvestChronicle
JPMorgan Chase & Co. Initiates Coverage on Alcoa (NYSE:AA) - Defense World
Tesla's Massive October Starts Next Week With Third-Quarter Deliveries - MSN
CRH plc (NYSE:CRH) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Increase in Short Interest - Defense World
Tesla's Robotaxi Launch: A Game-Changer For Stock Performance? - MSN
Tesla (TSLA) call put ratio 2.1 calls to 1 put with focus on October 285 and 325 calls into deliveries release for Q3 and Robotaxi meeting - StreetInsider.com
Commonwealth Financial Services LLC Acquires 95 Shares of Tesla, Inc. (NASDAQ:TSLA) - Defense World
Tesla: stock outperforms, buoyed by optimism from UBS - Marketscreener.com
Analysts praise groundbreaking Tesla rival, previews Robotaxi event - MSN
Tesla Stock Pops 5% To 2-Month High As Q3 Deliveries, Robotaxi Event Await - MSN
Tiziana Life Sciences Ltd (TLSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):